CXCL2 and adenoma: Among pro-inflammatory cytokines, CXCL2 expression was significantly lower in adenocarcinomas (p = 0.007) (Figure 5D, left panel), with paired analysis confirming this trend (67% of samples exhibited higher expression in adenomas, p = 0.0002) (Figure 5D, right panel).